Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blind, Placebo and Active Controlled, Parallel Crossover Study to Evaluate the Effect of Repeat Oral Doses of Mirabegron on Cardiac Repolarization in Healthy Male and Female Adult Subjects

NCT01199523 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01199523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01199523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blind, Placebo and Active Controlled, Parallel Crossover Study to Evaluate the Effect of Repeat Oral Doses of Mirabegron on Cardiac Repolarization in Healthy Male and Female Adult Subjects
Lead sponsor
Astellas Pharma Inc
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2010
Completion date
November 30, 2010
Enrollment
352 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy subjects